• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

芳基磺酰基吲唑衍生物作为 VEGFR2 激酶潜在配体的相互作用理论研究。

Theoretical Investigations on Interactions of Arylsulphonyl Indazole Derivatives as Potential Ligands of VEGFR2 Kinase.

机构信息

Chair and Department of Organic Chemistry, Faculty of Pharmacy, Poznan University of Medical Sciences, ul. Grunwaldzka 6, 60-780 Poznań, Poland.

Faculty of Chemical Engineering and Technology, Cracow University of Technology, ul. Warszawska 24, 31-155 Kraków, Poland.

出版信息

Int J Mol Sci. 2020 Jul 7;21(13):4793. doi: 10.3390/ijms21134793.

DOI:10.3390/ijms21134793
PMID:32645858
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7369845/
Abstract

Vascular endothelial growth factor receptor 2 (VEGFR2) is a key receptor in the angiogenesis process. The VEGFR2 expression is upregulated in many cancers so this receptor is an important target for anticancer agents. In the present paper, we analyse interactions of several dimeric indazoles, previously investigated for anticancer activity, with the amino acids present in the VEGFR2 binding pocket. Using the docking method and MD simulations as well as theoretical computations (SAPT0, PIEDA, semi-empirical PM7), we confirmed that these azoles can efficiently bind into the kinase pocket and their poses can be stabilised by the formation of hydrogen bonds, π-π stacking, π-cation, and hybrid interactions with some amino acids of the kinase cavity like Ala866, Lys868, Glu885, Thr916, Glu917, and Phe918.

摘要

血管内皮生长因子受体 2(VEGFR2)是血管生成过程中的关键受体。VEGFR2 的表达在许多癌症中上调,因此该受体是抗癌药物的重要靶点。在本文中,我们分析了几种先前研究过的二聚吲哚与 VEGFR2 结合口袋中存在的氨基酸的相互作用。使用对接方法和 MD 模拟以及理论计算(SAPT0、PIEDA、半经验 PM7),我们证实这些唑类化合物可以有效地结合到激酶口袋中,并且它们的构象可以通过形成氢键、π-π 堆积、π-阳离子和与激酶腔中的一些氨基酸(如 Ala866、Lys868、Glu885、Thr916、Glu917 和 Phe918)的混合相互作用来稳定。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80bc/7369845/44306507b4ce/ijms-21-04793-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80bc/7369845/31d55a5a1a38/ijms-21-04793-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80bc/7369845/7a7bb10761e7/ijms-21-04793-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80bc/7369845/a1b4daaccc0b/ijms-21-04793-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80bc/7369845/b9e4d573e896/ijms-21-04793-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80bc/7369845/ecc0bbdf9844/ijms-21-04793-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80bc/7369845/7308b35ca79f/ijms-21-04793-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80bc/7369845/a7a637d260f8/ijms-21-04793-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80bc/7369845/44306507b4ce/ijms-21-04793-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80bc/7369845/31d55a5a1a38/ijms-21-04793-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80bc/7369845/7a7bb10761e7/ijms-21-04793-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80bc/7369845/a1b4daaccc0b/ijms-21-04793-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80bc/7369845/b9e4d573e896/ijms-21-04793-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80bc/7369845/ecc0bbdf9844/ijms-21-04793-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80bc/7369845/7308b35ca79f/ijms-21-04793-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80bc/7369845/a7a637d260f8/ijms-21-04793-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80bc/7369845/44306507b4ce/ijms-21-04793-sch002.jpg

相似文献

1
Theoretical Investigations on Interactions of Arylsulphonyl Indazole Derivatives as Potential Ligands of VEGFR2 Kinase.芳基磺酰基吲唑衍生物作为 VEGFR2 激酶潜在配体的相互作用理论研究。
Int J Mol Sci. 2020 Jul 7;21(13):4793. doi: 10.3390/ijms21134793.
2
Selected arylsulphonyl pyrazole derivatives as potential Chk1 kinase ligands-computational investigations.作为潜在的 Chk1 激酶配体的芳基磺酰基吡唑衍生物的选择 - 计算研究。
J Mol Model. 2020 May 18;26(6):144. doi: 10.1007/s00894-020-04407-3.
3
Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.基于配体的药效团模型构建、EGFR 和 VEGFR2 双重酪氨酸激酶抑制剂的分子对接和分子动力学研究。
Int J Mol Sci. 2020 Oct 21;21(20):7779. doi: 10.3390/ijms21207779.
4
Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.激酶抑制剂与血管内皮生长因子受体-2(VEGFR-2)活性和非活性构象结合的分子动力学模拟及自由能计算研究
J Mol Graph Model. 2015 Mar;56:103-12. doi: 10.1016/j.jmgm.2014.12.006. Epub 2014 Dec 24.
5
Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity.具有抗血管生成和抗增殖抗癌活性的吲唑衍生物的设计、合成、生物评价和动力学模拟。
Bioorg Chem. 2019 Feb;82:340-359. doi: 10.1016/j.bioorg.2018.10.071. Epub 2018 Nov 2.
6
Discovery of octahydropyrrolo [3,2-b] pyridin derivative as a highly selective Type I inhibitor of FGFR3 over VEGFR2 by high-throughput virtual screening.通过高通量虚拟筛选发现八氢吡咯并[3,2 - b]吡啶衍生物作为一种对FGFR3的选择性远高于VEGFR2的I型抑制剂。
J Cell Biochem. 2023 Feb;124(2):221-238. doi: 10.1002/jcb.30357. Epub 2022 Dec 11.
7
Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.基于分子动力学的深入洞察、结合自由能计算和药效团虚拟筛选以鉴定潜在的血管内皮生长因子受体2(VEGFR2)抑制剂
J Recept Signal Transduct Res. 2019 Oct-Dec;39(5-6):415-433. doi: 10.1080/10799893.2019.1690509. Epub 2019 Nov 22.
8
Exploring the Molecular Interactions of 7,8-Dihydroxyflavone and Its Derivatives with TrkB and VEGFR2 Proteins.探索7,8-二羟基黄酮及其衍生物与TrkB和VEGFR2蛋白的分子相互作用。
Int J Mol Sci. 2015 Sep 3;16(9):21087-108. doi: 10.3390/ijms160921087.
9
Discovery of Small Molecules that Target Vascular Endothelial Growth Factor Receptor-2 Signalling Pathway Employing Molecular Modelling Studies.采用分子建模研究发现靶向血管内皮生长因子受体-2 信号通路的小分子。
Cells. 2019 Mar 21;8(3):269. doi: 10.3390/cells8030269.
10
Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations.采用分子对接机制和分子动力学模拟探索针对 VEGFR-2 激酶结构域(4AG8)的新型反向抑制剂。
BMC Cancer. 2018 Mar 7;18(1):264. doi: 10.1186/s12885-018-4050-1.

引用本文的文献

1
Design, synthesis, and evaluation of novel thiadiazole derivatives as potent VEGFR-2 inhibitors: a comprehensive and study.新型噻二唑衍生物作为强效血管内皮生长因子受体-2(VEGFR-2)抑制剂的设计、合成及评价:一项全面的研究
RSC Adv. 2024 Nov 6;14(48):35505-35519. doi: 10.1039/d4ra04158e. eCollection 2024 Nov 4.
2
-chalcones obtained one-pot synthesis as the anti-neurodegenerative agents and their effect on the HT-22 cell line.查耳酮通过一锅法合成作为抗神经退行性疾病药物及其对HT-22细胞系的作用。
Heliyon. 2024 Aug 30;10(17):e37147. doi: 10.1016/j.heliyon.2024.e37147. eCollection 2024 Sep 15.
3
Controlling the Polymorphism of Indomethacin with Poloxamer 407 in a Gas Antisolvent Crystallization Process.

本文引用的文献

1
Selected arylsulphonyl pyrazole derivatives as potential Chk1 kinase ligands-computational investigations.作为潜在的 Chk1 激酶配体的芳基磺酰基吡唑衍生物的选择 - 计算研究。
J Mol Model. 2020 May 18;26(6):144. doi: 10.1007/s00894-020-04407-3.
2
The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.成纤维细胞生长因子受体(FGFR)蛋白酪氨酸激酶抑制剂在包括膀胱癌在内的癌症治疗中的作用。
Pharmacol Res. 2020 Jan;151:104567. doi: 10.1016/j.phrs.2019.104567. Epub 2019 Nov 23.
3
Revisiting NTRKs as an emerging oncogene in hematological malignancies.
在气体抗溶剂结晶过程中用泊洛沙姆407控制吲哚美辛的多晶型
ACS Omega. 2022 Nov 18;7(48):43945-43957. doi: 10.1021/acsomega.2c05259. eCollection 2022 Dec 6.
4
Resveratrol Analogues as Selective Estrogen Signaling Pathway Modulators: Structure-Activity Relationship.白藜芦醇类似物作为选择性雌激素信号通路调节剂:构效关系。
Molecules. 2022 Oct 17;27(20):6973. doi: 10.3390/molecules27206973.
5
Current progress, challenges and future prospects of indazoles as protein kinase inhibitors for the treatment of cancer.吲唑类作为治疗癌症的蛋白激酶抑制剂的当前进展、挑战及未来前景
RSC Adv. 2021 Jul 20;11(41):25228-25257. doi: 10.1039/d1ra03979b. eCollection 2021 Jul 19.
6
Conjugation of Diclofenac with Novel Oleanolic Acid Derivatives Modulate Nrf2 and NF-κB Activity in Hepatic Cancer Cells and Normal Hepatocytes Leading to Enhancement of Its Therapeutic and Chemopreventive Potential.双氯芬酸与新型齐墩果酸衍生物的共轭作用调节肝癌细胞和正常肝细胞中的Nrf2和NF-κB活性,从而增强其治疗和化学预防潜力。
Pharmaceuticals (Basel). 2021 Jul 17;14(7):688. doi: 10.3390/ph14070688.
重新审视 NTRKs 作为血液系统恶性肿瘤中新兴的癌基因。
Leukemia. 2019 Nov;33(11):2563-2574. doi: 10.1038/s41375-019-0576-8. Epub 2019 Sep 24.
4
Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK).针对间变性淋巴瘤激酶(ALK)的药物发现。
J Med Chem. 2019 Dec 26;62(24):10927-10954. doi: 10.1021/acs.jmedchem.9b00446. Epub 2019 Aug 26.
5
Protein-ligand interaction-guided discovery of novel VEGFR-2 inhibitors.基于蛋白-配体相互作用的新型 VEGFR-2 抑制剂发现。
J Biomol Struct Dyn. 2020 Jun;38(9):2559-2574. doi: 10.1080/07391102.2019.1635915. Epub 2019 Jul 2.
6
Recognition of repulsive and attractive regions of selected serotonin receptor binding site using FMO-EDA approach.使用 FMO-EDA 方法识别选定的 5-羟色胺受体结合位点的排斥和吸引区域。
J Mol Model. 2019 Apr 6;25(5):114. doi: 10.1007/s00894-019-3995-6.
7
Properties of FDA-approved small molecule protein kinase inhibitors.已批准用于临床的小分子蛋白激酶抑制剂的特性。
Pharmacol Res. 2019 Jun;144:19-50. doi: 10.1016/j.phrs.2019.03.006. Epub 2019 Mar 13.
8
VEGF in Signaling and Disease: Beyond Discovery and Development.血管内皮生长因子在信号转导和疾病中的作用:超越发现和开发。
Cell. 2019 Mar 7;176(6):1248-1264. doi: 10.1016/j.cell.2019.01.021.
9
Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.合成、抗癌作用及新型噻唑基吡唑并香豆素衍生物的分子模拟,该衍生物针对 VEGFR-2 激酶并诱导细胞周期停滞和细胞凋亡。
Bioorg Chem. 2019 Apr;85:253-273. doi: 10.1016/j.bioorg.2018.12.040. Epub 2019 Jan 3.
10
Recent Advances in the Development of Indazole-based Anticancer Agents.吲哚嗪类抗癌剂的最新研究进展。
ChemMedChem. 2018 Aug 10;13(15):1490-1507. doi: 10.1002/cmdc.201800253. Epub 2018 Jun 26.